Evidence updated August 10, 2026. Compounded semaglutide and an FDA-approved medicine are not the same regulatory or product category. A compounded drug is not FDA-approved, is not an FDA-approved generic, and does not receive FDA premarket review for safety, effectiveness, and quality. Approval and evidence attached to a specific branded product do not automatically transfer to a compounded preparation.
That distinction does not tell an individual which option is appropriate. It tells you what must stay visible before you compare a name, price, delivery system, study, or treatment claim. A licensed provider owns the individual decision, and the exact dispensing pharmacy and preparation still matter.
The short answer: ingredient language is not a complete product identity
“Semaglutide” can appear as an ingredient name in conversations about more than one product or preparation. That shared word can make unlike categories look interchangeable. They are not.
An FDA-approved medicine is a specific product with an approved application and current product-specific labeling. For example, the current Wegovy prescribing information identifies the exact product, dosage forms, uses, limitations, boxed warning, contraindications, warnings, adverse reactions, and administration information. The label was revised in June 2026. Those details belong to that product and label.
A compounded preparation is made through a different pathway. The FDA states that compounded drugs are not FDA-approved, are not FDA-approved generic drugs, and are not verified by FDA for safety, effectiveness, or quality before marketing. A compounder's work may address a patient's medical need that cannot be met by an FDA-approved drug, but that possibility is a provider-owned judgment—not a reason to erase the category difference.
Use a Category Identity Card before comparing options
The Category Identity Card is an editorial reading tool. It does not score quality, diagnose a need, establish legal status, recommend treatment, or replace a provider or pharmacist.
| Identity line | FDA-approved medicine | Compounded preparation |
|---|---|---|
| Exact name | Record the specific brand, dosage form, and current label. | Record the exact preparation, ingredients, concentration, dosage form, and dispensing pharmacy shown on the prescription and label. |
| Regulatory category | The specific product has an FDA-approved application. | The preparation is not FDA-approved and is not an FDA-approved generic. |
| Evidence boundary | Product-specific evidence and labeling support only the claims and conditions they actually address. | Do not transfer an approved product's evidence, equivalence, delivery, or label claims to the preparation without exact support. |
| Directions and delivery | Use the current product-specific prescription and approved labeling. | Use only the exact prescriber and pharmacy directions for the dispensed preparation; do not borrow a branded device or unit conversion. |
| Decision owner | A licensed provider decides whether treatment and any prescription are appropriate for an individual. The dispensing pharmacy owns preparation and label questions within its role. | |
If a comparison cannot fill every line, the product identity is incomplete. A molecule name, a monthly-looking price, a social post, or a before-and-after image cannot fill the missing fields.
What FDA approval does—and does not—mean in this comparison
FDA approval applies to a specific product, not to every item that uses similar ingredient language. The approval process and approved label establish a bounded product identity. They do not mean that the medicine is risk-free, suitable for everyone, or appropriate without licensed review. The current Wegovy label, for example, contains a boxed warning, contraindications, warnings, and adverse reactions alongside its approved uses.
The useful comparison is therefore not “approved equals safe” and “compounded equals unsafe.” That would be an unsupported individual conclusion. The accurate distinction is that an approved product underwent FDA review for the specific application, while a compounded drug did not undergo that premarket review.
The FTC Health Products Compliance Guidance also requires marketers to support objective express and implied health claims and to evaluate the message as a whole. A small disclaimer cannot repair a headline, image, price card, or testimonial that otherwise implies FDA approval, equivalence, guaranteed access, safety, or results.
Why “generic semaglutide” is not an accurate shortcut for a compound
FDA-approved generic drugs follow an approval pathway that includes requirements such as therapeutic equivalence to a reference drug. The FDA's compounding Q&A says a compounded drug is not approved under that generic-drug pathway.
That makes “generic Wegovy,” “generic Ozempic,” or “FDA-approved compounded semaglutide” inaccurate descriptions of a compounded preparation. It also means that a compound should not be called the same, equivalent, interchangeable, or identical to an approved product unless an exact controlling authority supports that exact claim. CMH makes none of those claims.
Four comparison mistakes that change the complete impression
- Comparing only the ingredient word. A product identity also includes its regulatory category, formulation, dosage form, concentration, delivery system, label, and source.
- Borrowing a branded study or result. Evidence for one exact product, population, use, and outcome does not prove the same claim for a different preparation.
- Borrowing branded directions. Concentrations, containers, syringes, pens, tablets, and written instructions can differ. Do not calculate or transfer dosing instructions between products.
- Letting price imply sameness. A lower, higher, monthly, prepaid, medication-only, or bundled price does not establish approval status, equivalence, quality, individual fit, availability, or expected results.
For a bounded commercial comparison, CMH's semaglutide cash-price guide keeps current compounded-product identity, payment cadence, and commercial scope attached to the number. It does not convert that price into an approved-brand comparison.
Current FDA concerns worth recognizing without self-diagnosing
The FDA's current page on unapproved GLP-1 drugs used for weight loss reports concerns involving unapproved semaglutide products. Among them:
- unapproved versions do not undergo FDA premarket review for safety, effectiveness, and quality;
- FDA has received adverse-event reports, some involving hospitalization, that may relate to dosing errors with compounded injectable semaglutide;
- concentrations, containers, and instructions can create measurement or calculation confusion; and
- semaglutide sodium and semaglutide acetate are different active ingredients from the active ingredient used in approved drugs, and FDA says it lacks information showing the same chemical and pharmacologic properties.
These are category-level safety signals, not a diagnosis, a judgment about an unnamed preparation, or instructions for changing treatment. If a dispensed label, concentration, syringe marking, written direction, or ingredient name is unclear, do not improvise a conversion. Use the secure clinical and pharmacy channels assigned to the prescription.
Questions that keep the product identity intact
- What is the exact name and regulatory category? Ask whether the item is a specific FDA-approved branded product or a compounded preparation.
- What exact ingredients and dosage form appear on the prescription and dispensing label? Do not rely on an ad headline or shortened checkout name.
- Which pharmacy dispenses it? Verify the pharmacy shown in the care and fulfillment documents rather than borrowing another company's pharmacy claim.
- What written directions govern this exact item? Keep the provider and pharmacy directions with the actual concentration and delivery system.
- What evidence supports the exact claim being made? Separate product-specific label evidence from ingredient-level discussion and from marketing.
- What is not promised? Approval, prescription, availability, uninterrupted supply, a particular dose, safety, tolerability, response, or result should never be inferred from category language.
These questions organize a conversation; they do not answer it. Side effects, symptoms, interactions, contraindications, dose questions, and treatment changes belong with the licensed medical team through the approved secure route. Do not place private health information in public comments, social messages, ordinary email, or generic forms.
How the distinction applies to Concordia Men's Health
CMH's current source-controlled launch offering identifies injectable Compounded Semaglutide with cyanocobalamin. It is a compounded preparation. CMH does not call it Wegovy, Ozempic, Rybelsus, FDA-approved, generic, equivalent, interchangeable, or the same as an approved product.
The GLP-1 decision guide explains how product identity, evidence, provider authority, and follow-up fit together. The provider-review guide explains why a website, questionnaire, price, or algorithm does not make the individual clinical decision. The current FAQ and CMH overview describe the public process and commercial boundaries.
The direct assessment link is omitted because its automated first-step check remains blocked. This article does not reinterpret that defect, promise treatment access, or represent the intake handoff as validated end to end.
The category difference is the beginning of a useful comparison
Compounded semaglutide and FDA-approved medicines are not the same category. Keep the exact product or preparation, approval status, label, pharmacy, written directions, evidence boundary, and provider authority visible at the same time.
This article is general education, not medical, pharmacy, regulatory, or legal advice. It does not diagnose, determine eligibility, recommend or select treatment, provide dosing or interaction guidance, compare individual risk, or promise approval, prescription, medication, availability, safety, effectiveness, or results. Individual decisions belong to a licensed provider using complete information about the person and the exact product or preparation.